Marketed products in the GI space
Marketed product in the GI space (idiopathic bowel syndrome, diarrhea, opioid induced constipation) available for acquisition. Client will also consider a distribution partnership.
See Below for More
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png)
505(b)(2) formulation for chemotherapy available in-licensing
505(b)(2) formulation for the treatment of chemotherapy induced nausea and vomiting. Multiple advantages over currently available products including the ability to use without further reconstitution.
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png)
505(b)(2) formulation for schizophrenia available in-licensing
505(b)(2) formulation for schizophrenia available for in-licensing:
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/Manufacture-icon.png)
Oral Solid Dose (OSD) Tablets & Capsules facility Sale
Oral Solid Dose (OSD) Tablets & Capsules facility, 45 minutes from Boston, with $20 million in facility value / equipment. Asset Overview Opportunity
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/Manufacture-icon.png)
Nanoparticle Processing Technology Company Immediate Acquisition
University-owned high-throughput, nanoparticle processing technology company. Continuous Manufacturing of Nanomedicines:
Ready for Immediate Acquisition
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/Manufacture-icon.png)
Self-amplifying RNA (saRNA) Virtual Biotech seeks VC
Self-amplifying RNA (saRNA) Virtual Biotech seeks VC investment to develop a pipeline of RNA therapeutics and vaccines.
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/Manufacture-icon.png)
Phase III plasma-derived Therapeutic Company Raise Capital
Private-Equity owned, Phase III plasma-derived therapeutic company is ready to build the commercial facility with One Million Liter annual capacity, in Dallas Texas Looking to Raise Capital
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/Manufacture-icon.png)
Non-cGMP API Starting Material Company Asset Opportunity
Non-cGMP API Drug Development Starting Materials + API Pilot
Plant and cGMP CDMO: Ready for Immediate Acquisition with operations in Jaipur, India and Birmingham, Alabama
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/505-icon.png)
Approved 505(b)(2) available for in-licensing
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space. US rights only.
![](https://commercialhealthcarepartners.com/wp-content/uploads/2021/10/Manufacture-icon.png)
Marketed products in the GI space
Marketed product in the GI space (idiopathic bowel syndrome, diarrhea, opioid induced constipation) available for acquisition. Client will also consider a distribution partnership.